Press Releases

Date Title and Summary Additional Formats
Toggle Summary SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be Read All » View HTML
Toggle Summary Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells Read All » View HTML
Toggle Summary First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Convenes PROTECT Data Monitoring Committee for ProTmune™ Read All » View HTML
Toggle Summary SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All » View HTML
Toggle Summary Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate FDA Clears IND for FATE-NK100 in Ovarian Cancer SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the Read All » View HTML
Toggle Summary SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary ProTmune™ PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced Solid Tumors Conducted Formal Regulatory Meetings with FDA and MHRA for Engineered Read All » View HTML
Toggle Summary SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All » View HTML
Toggle Summary SAN DIEGO, May 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary New Preclinical Data to be Presented on First-of-Kind Product Candidates Derived from Master Engineered Pluripotent Cell Lines Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.